Click here to get full coverage on Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation  Yahoo Finance

Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation  Nasdaq

Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

Click here to get full coverage on $LRMR stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

$LRMR stock is up 15% today. Here's what we see in our data.  Quiver Quantitative

$LRMR stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR - Business Wire

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR  Business Wire

Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR - Business Wire

Click here to get full coverage on Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st

Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners  simplywall.st

Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners - simplywall.st

Click here to get full coverage on LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm  GlobeNewswire

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Click here to get full coverage on Rare Disease Biotech Larimar Therapeutics Unveils Strategic Public Offering for Breakthrough Drug Development - Stock Titan

Rare Disease Biotech Larimar Therapeutics Unveils Strategic Public Offering for Breakthrough Drug Development  Stock Titan

Rare Disease Biotech Larimar Therapeutics Unveils Strategic Public Offering for Breakthrough Drug Development - Stock Titan

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR - PR Newswire

Click here to get full coverage on With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest  Yahoo Finance

With 40% stake, Larimar Therapeutics, Inc. (NASDAQ:LRMR) seems to have captured institutional investors' interest - Yahoo Finance

Click here to get full coverage on Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2025 Financial Results  GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES - PR Newswire

MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES  PR Newswire

MATTHEW BERRY'S FANTASY LIFE CLOSES $7 MILLION SEED ROUND LED BY LRMR VENTURES AND SC HOLDINGS; UNVEILS NEW PLATFORM AND GUILLOTINE LEAGUES - PR Newswire

Click here to get full coverage on Rare Disease Biotech Larimar to Present Long-term Data for Breakthrough Friedreich's Ataxia Drug - Stock Titan

Rare Disease Biotech Larimar to Present Long-term Data for Breakthrough Friedreich's Ataxia Drug  Stock Titan

Rare Disease Biotech Larimar to Present Long-term Data for Breakthrough Friedreich's Ataxia Drug - Stock Titan

Click here to get full coverage on Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance

Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment?  Yahoo Finance

Will Positive Nomlabofusp Study Results Alter Larimar Therapeutics' (LRMR) Standing in Rare Disease Treatment? - Yahoo Finance

Click here to get full coverage on Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement | LRMR Stock News - Quiver Quantitative

Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement | LRMR Stock News  Quiver Quantitative

Larimar Therapeutics Stock (LRMR) Opinions on Public Offering Announcement | LRMR Stock News - Quiver Quantitative

Click here to get full coverage on Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?  Yahoo Finance

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $LRMR Given $7.0 Price Target - Quiver Quantitative

New Analyst Forecast: $LRMR Given $7.0 Price Target  Quiver Quantitative

New Analyst Forecast: $LRMR Given $7.0 Price Target - Quiver Quantitative

Click here to get full coverage on Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings - RTTNews

Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings  RTTNews

Morning Market Movers: JFB, MLTX, MTEK, LRMR, MRUS See Big Swings - RTTNews

Click here to get full coverage on Larimar Therapeutics Announces Proposed Underwritten Public Offering - GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering  GlobeNewswire

Larimar Therapeutics Announces Proposed Underwritten Public Offering - GlobeNewswire

Click here to get full coverage on Bull Run: What sentiment indicators say about LRMR stock - Quarterly Profit Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn

Bull Run: What sentiment indicators say about LRMR stock - Quarterly Profit Report & Free Real-Time Market Sentiment Alerts  moha.gov.vn

Bull Run: What sentiment indicators say about LRMR stock - Quarterly Profit Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn

Click here to get full coverage on 100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - Stock Titan

100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential  Stock Titan

100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential - Stock Titan

Click here to get full coverage on Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia - Quiver Quantitative

Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia  Quiver Quantitative

Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia - Quiver Quantitative

Click here to get full coverage on LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus

LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 |  GuruFocus

LRMR: Baird Maintains Rating but Lowers Price Target to $7.00 | - GuruFocus

Click here to get full coverage on Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus

Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) | LRMR Stock News  GuruFocus

Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus

Click here to get full coverage on Larimar Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2025 Financial Results  GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates - Quiver Quantitative

Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates  Quiver Quantitative

Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates - Quiver Quantitative

Click here to get full coverage on First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval  Stock Titan

First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan

Click here to get full coverage on Breakthrough: FDA Outlines Requirements for First-Ever Friedreich's Ataxia Disease-Modifying Drug - Stock Titan

Breakthrough: FDA Outlines Requirements for First-Ever Friedreich's Ataxia Disease-Modifying Drug  Stock Titan

Breakthrough: FDA Outlines Requirements for First-Ever Friedreich's Ataxia Disease-Modifying Drug - Stock Titan

Click here to get full coverage on Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

Larimar Therapeutics Reports First Quarter 2025 Financial Results  GlobeNewswire

Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on JMP reiterates Market Outperform rating on Larimar stock despite safety concerns - Investing.com

JMP reiterates Market Outperform rating on Larimar stock despite safety concerns  Investing.com

JMP reiterates Market Outperform rating on Larimar stock despite safety concerns - Investing.com

Click here to get full coverage on Larimar stock falls as anaphylaxis events overshadow positive frataxin data - Investing.com

Larimar stock falls as anaphylaxis events overshadow positive frataxin data  Investing.com

Larimar stock falls as anaphylaxis events overshadow positive frataxin data - Investing.com

Click here to get full coverage on Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition? - simplywall.st

Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition?  simplywall.st

Do Positive Friedreich's Ataxia Study Results Shift Larimar Therapeutics’ (LRMR) Long-Term Value Proposition? - simplywall.st

Click here to get full coverage on Citizens reiterates Market Outperform rating on Larimar stock ahead of FA discussion - Investing.com

Citizens reiterates Market Outperform rating on Larimar stock ahead of FA discussion  Investing.com

Citizens reiterates Market Outperform rating on Larimar stock ahead of FA discussion - Investing.com

Click here to get full coverage on Larimar Therapeutics stock price target lowered to $7 at Jones Trading - Investing.com

Larimar Therapeutics stock price target lowered to $7 at Jones Trading  Investing.com

Larimar Therapeutics stock price target lowered to $7 at Jones Trading - Investing.com

Click here to get full coverage on Larimar Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com

Larimar Therapeutics stock rating reiterated at Market Outperform by Citizens  Investing.com

Larimar Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com

Click here to get full coverage on Larimar Therapeutics Announces Pricing of Underwritten Public Offering - GlobeNewswire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering  GlobeNewswire

Larimar Therapeutics Announces Pricing of Underwritten Public Offering - GlobeNewswire

Click here to get full coverage on LRMR Shares Promising Data for Friedreich's Ataxia Treatment - GuruFocus

LRMR Shares Promising Data for Friedreich's Ataxia Treatment  GuruFocus

LRMR Shares Promising Data for Friedreich's Ataxia Treatment - GuruFocus

Click here to get full coverage on Guggenheim reiterates Buy rating on Larimar Therapeutics stock with $26 target - Investing.com

Guggenheim reiterates Buy rating on Larimar Therapeutics stock with $26 target  Investing.com

Guggenheim reiterates Buy rating on Larimar Therapeutics stock with $26 target - Investing.com

Click here to get full coverage on Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga

Top 3 Health Care Stocks That May Rocket Higher In December  Benzinga

Top 3 Health Care Stocks That May Rocket Higher In December - Benzinga

Click here to get full coverage on Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data - TipRanks

Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data  TipRanks

Larimar Therapeutics Highlights Promising Friedreich’s Ataxia Data - TipRanks

Click here to get full coverage on Larimar Therapeutics stock falls after $60 million public offering - Investing.com

Larimar Therapeutics stock falls after $60 million public offering  Investing.com

Larimar Therapeutics stock falls after $60 million public offering - Investing.com

Click here to get full coverage on Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study - Benzinga

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study  Benzinga

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study - Benzinga

Click here to get full coverage on Larimar Prices $60 Mln Public Offering Of 18.75M Shares At $3.20 Each - Nasdaq

Larimar Prices $60 Mln Public Offering Of 18.75M Shares At $3.20 Each  Nasdaq

Larimar Prices $60 Mln Public Offering Of 18.75M Shares At $3.20 Each - Nasdaq

Click here to get full coverage on Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? - simplywall.st

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?  simplywall.st

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans? - simplywall.st

Click here to get full coverage on Larimar Therapeutics Announces Positive Study Results - TipRanks

Larimar Therapeutics Announces Positive Study Results  TipRanks

Larimar Therapeutics Announces Positive Study Results - TipRanks

Click here to get full coverage on Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential reshapes FA stock outlook - Investing.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential reshapes FA stock outlook  Investing.com

Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential reshapes FA stock outlook - Investing.com

Click here to get full coverage on Bronstein, Gewirtz & Grossman, LLC Is Investigating Larimar Therapeutics, Inc. (LRMR) And Encourages Stockholders to Connect - ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Larimar Therapeutics, Inc. (LRMR) And Encourages Stockholders to Connect  ACCESS Newswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Larimar Therapeutics, Inc. (LRMR) And Encourages Stockholders to Connect - ACCESS Newswire

Click here to get full coverage on LeBron James, Maverick Carter lead $7M investment in Matthew Berry’s Fantasy Life - Awful Announcing

LeBron James, Maverick Carter lead $7M investment in Matthew Berry’s Fantasy Life  Awful Announcing

LeBron James, Maverick Carter lead $7M investment in Matthew Berry’s Fantasy Life - Awful Announcing

Click here to get full coverage on Larimar Therapeutics Updates on Nomlabofusp Progress - TipRanks

Larimar Therapeutics Updates on Nomlabofusp Progress  TipRanks

Larimar Therapeutics Updates on Nomlabofusp Progress - TipRanks

Click here to get full coverage on Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - Stocktwits

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study  Stocktwits

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study - Stocktwits

Click here to get full coverage on Massive Stock Purchase by Larimar Therapeutics Director! - TipRanks

Massive Stock Purchase by Larimar Therapeutics Director!  TipRanks

Massive Stock Purchase by Larimar Therapeutics Director! - TipRanks

Click here to get full coverage on Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock | LRMR Stock News - Quiver Quantitative

Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock | LRMR Stock News  Quiver Quantitative

Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock | LRMR Stock News - Quiver Quantitative

Click here to get full coverage on Larimar Therapeutics stock plunges after anaphylaxis cases in FA study - Investing.com

Larimar Therapeutics stock plunges after anaphylaxis cases in FA study  Investing.com

Larimar Therapeutics stock plunges after anaphylaxis cases in FA study - Investing.com

Click here to get full coverage on Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview - TradingView — Track All Markets

Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview  TradingView — Track All Markets

Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview - TradingView — Track All Markets

Click here to get full coverage on Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program - GlobeNewswire

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program  GlobeNewswire

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich’s Ataxia Program - GlobeNewswire

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts  Seeking Alpha

Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha

Click here to get full coverage on The Best AI for Picking Stocks, Ranked by Performance - MarketBeat

The Best AI for Picking Stocks, Ranked by Performance  MarketBeat

The Best AI for Picking Stocks, Ranked by Performance - MarketBeat

Click here to get full coverage on Larimar Therapeutics stock plunges after anaphylaxis cases in FA study By Investing.com - Investing.com South Africa

Larimar Therapeutics stock plunges after anaphylaxis cases in FA study By Investing.com  Investing.com South Africa

Larimar Therapeutics stock plunges after anaphylaxis cases in FA study By Investing.com - Investing.com South Africa

Click here to get full coverage on Larimar Therapeutics stock price target lowered to $10 at Jones Trading - Investing.com

Larimar Therapeutics stock price target lowered to $10 at Jones Trading  Investing.com

Larimar Therapeutics stock price target lowered to $10 at Jones Trading - Investing.com

Click here to get full coverage on Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment - TipRanks

Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment  TipRanks

Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment - TipRanks

Click here to get full coverage on Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better (NASDAQ:LRMR) - Seeking Alpha

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better (NASDAQ:LRMR)  Seeking Alpha

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better (NASDAQ:LRMR) - Seeking Alpha

Click here to get full coverage on Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics  Yahoo Finance

Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance

Click here to get full coverage on Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment | LRMR Stock News - Quiver Quantitative

Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment | LRMR Stock News  Quiver Quantitative

Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment | LRMR Stock News - Quiver Quantitative

Click here to get full coverage on Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference  GlobeNewswire

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Click here to get full coverage on 5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - Yahoo Finance

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats  Yahoo Finance

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - Yahoo Finance

Click here to get full coverage on LRMR Stock Price and Chart — NASDAQ:LRMR - TradingView — Track All Markets

LRMR Stock Price and Chart — NASDAQ:LRMR  TradingView — Track All Markets

LRMR Stock Price and Chart — NASDAQ:LRMR - TradingView — Track All Markets

Click here to get full coverage on Here's Why You Should Invest in Larimar (LRMR) Stock Now - Yahoo Finance

Here's Why You Should Invest in Larimar (LRMR) Stock Now  Yahoo Finance

LRMR

Price Chart

Key Statistics

Technicals

About LRMR

Latest News

Here's Why We're Watching Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation - Yahoo Finance

Wedbush Maintains Larimar Therapeutics (LRMR) Outperform Recommendation - Nasdaq

$LRMR stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers